Iothalamic Acid

Iothalamic Acid

SCHEMBL180546

CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TACR1TTRgyrAgyrBparCparE

The experimentally established mechanism targets of Iothalamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.84
LMNA P02545 6/20 0.43
KDM4E B2RXH2 2/20 0.43
HIF1A Q16665 2/20 0.32
CYP2C19 P33261 1/20 0.32
CYP1A2 P05177 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iothalamic Acid SCHEMBL48785 1.00 SMN1; SMN2 (0.84) SMN1; SMN2LMNAKDM4EHIF1ACYP2C19
Iothalamic Acid SCHEMBL29488709 1.00 SMN1; SMN2 (0.84) SMN1; SMN2LMNAKDM4EHIF1ACYP2C19
Iothalamic Acid SCHEMBL3060866 0.99 SMN1; SMN2 (0.83) SMN1; SMN2LMNAKDM4EHIF1ACYP2C19
Diatrizoic Acid SCHEMBL720469 0.92 SMN1; SMN2 (1.00) SMN1; SMN2LMNAKDM4EHIF1ACYP1A2
Diatrizoic Acid SCHEMBL1685085 0.92 SMN1; SMN2 (1.00) SMN1; SMN2LMNAKDM4EHIF1ACYP1A2
Diatrizoic Acid SCHEMBL107036 0.92 SMN1; SMN2 (1.00) SMN1; SMN2LMNAKDM4EHIF1ACYP1A2
Diatrizoic Acid SCHEMBL2501947 0.91 SMN1; SMN2 (0.97) SMN1; SMN2LMNAKDM4EHIF1ACYP1A2
Diatrizoic Acid SCHEMBL468613 0.91 SMN1; SMN2 (0.97) SMN1; SMN2LMNAKDM4EHIF1ACYP1A2
Ioxitalamic Acid SCHEMBL29730019 0.89 SMN1; SMN2 (0.78) SMN1; SMN2LMNAKDM4EHIF1ACYP2C19
Iocarmic Acid SCHEMBL29886627 0.88 SMN1; SMN2 (0.65) SMN1; SMN2LMNAKDM4EHIF1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 989 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025124483-A1 ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF Triastek, Inc. (CN) 2025-06-19 WO claimed
EP-4543498-A2 COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING Suntec Medical, Inc. (US) 2025-04-30 EP claimed
US-20250121100-A1 COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING SUNTEC MEDICAL INC (US) 2025-04-17 US claimed
CN-119698306-A Compositions and methods for diagnostic imaging 欣扬生医股份有限公司 2025-03-25 CN claimed
US-20240282425-A1 AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS LOW GORDON KEITH (US) 2024-08-22 US claimed
WO-2023250377-A2 COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING SUNTEC MEDICAL, INC. (US) 2023-12-28 WO claimed
CN-210249862-U Earplug for external auditory canal CT scanning and positioning 中国人民解放军总医院第八医学中心 2020-04-07 CN claimed
US-10245446-B2 Marker-flange for MRI-guided brachytherapy UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2019-04-02 US claimed
EP-3234000-A1 CHITOSAN-BASED HYDROGEL AND APPLICATIONS THEREOF Socovar, L.P. (CA) 2017-10-25 EP claimed
CN-107115534-A A kind of intestines and stomach diagnostic imaging imaging assistant and preparation method thereof 山东赛克赛斯生物科技有限公司 2017-09-01 CN claimed
US-5989198-A Use of capillary electrophoresis to determine glomerular filtration rate using iothalamate MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 1999-11-23 US claimed
EP-0752894-B1 PRE-FILLED SYRINGE WITH LUGS NYCOMED IMAGING AS (NO) 1998-12-30 EP claimed
EP-0752894-A1 PRE-FILLED SYRINGE WITH LUGS NYCOMED IMAGING AS (NO) 1997-01-15 EP claimed
EP-0752832-A1 MEASUREMENT OF NUCLEOUS MATERIALS REMOVED DURING DISCECTOMY HOWMEDICA INC. (US) 1997-01-15 EP claimed
US-5535746-A Prefilled syringe for use with power injector STERLING WINTHROP INC. (US) 1996-07-16 US claimed
EP-0684786-A1 FIDUCIAL MARKER McCrory, Jennifer J. (US) 1995-12-06 EP claimed
WO-1995026689-A1 MEASUREMENT OF NUCLEOUS MATERIALS REMOVED DURING DISCECTOMY HOWMEDICA INC. (US) 1995-10-12 WO claimed
WO-1995026211-A1 PRE-FILLED SYRINGE WITH LUGS NYCOMED IMAGING AS (NO) 1995-10-05 WO claimed
US-5377681-A In an organ of a patient UNIVERSITY OF FLORIDA (US) 1995-01-03 US claimed
WO-1994017733-A1 FIDUCIAL MARKER MCCRORY, JENNIFER, J. (US) 1994-08-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250121100-A1 COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING ABCB4, C5, APOB SMN1; SMN2 2359/4885LMNA 793/4885KDM4E 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.